Unmet Needs in HR-Positive Metastatic Breast Cancer - Episode 1

CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer

Now Viewing
EP. 1: CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer
EP. 2: Selecting Agents in CDK4/6 Inhibition for HR+ mBC
EP. 3: HR+ mBC: Factors in Selecting CDK4/6 Inhibitions
EP. 4: HR+ mBC: Treatment After Progression on CDK4/6 Inhibition
EP. 5: Do CDK4/6 Inhibitors Impact Later Therapy in HR+ mBC?
EP. 6: PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer
EP. 7: Developments in Chemotherapy for HR+ mBC
EP. 8: Optimizing Selection of Chemotherapy for HR+ mBC
EP. 9: Tesetaxel: An Oral Taxane for HR+ mBC
EP. 10: HR+ mBC: Considering the Data and Potential of Tesetaxel
EP. 11: Tesetaxel in Doublet Therapy for HR+ mBC
EP. 12: HR+ mBC: Oral Formulations of Docetaxel and Paclitaxel

Transcript:

Transcript Edited for Clarity